Edgewise Therapeutics, INC Form 4 insider transactions

Michael Nofi, Chief Financial Officer of Edgewise Therapeutics, Inc., reported multiple transactions in common stock on August 12, 2026.

Joanne M. Donovan, CMO of Edgewise Therapeutics, Inc., sold 9,441 shares of common stock on August 12, 2026.

Alan J Russell, Chief Scientific Officer and a Director of Edgewise Therapeutics, Inc., sold 5,901 shares of common stock on August 12, 2026.

John R Moore, General Counsel of Edgewise Therapeutics, Inc., sold 5,016 shares of common stock on August 12, 2026.

Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, Inc., sold 5,100 shares of common stock on August 12, 2026.

Kevin Koch, President and CEO and a Director of Edgewise Therapeutics, Inc., sold 17,971 shares of common stock on August 12, 2026.

Jonathan D Root, a Director of Edgewise Therapeutics, Inc., received 16,377 shares of common stock on June 5, 2026.

Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock and stock options on July 1, 2026.

Jonathan C. Fox, a Director at Edgewise Therapeutics, Inc., received a restricted stock unit award on July 1, 2026, as part of his quarterly retainer.

Director Laura Brege was granted 16,377 stock options in Edgewise Therapeutics, Inc. as part of a standard equity compensation arrangement.

Peter A. Thompson, a Director and 10% Owner of Edgewise Therapeutics, Inc., acquired stock options on June 5, 2026, with a vesting schedule tied to future annual meetings.

Arlene Morris, a Director at Edgewise Therapeutics, Inc., reported the acquisition of stock options on June 5, 2026, with vesting conditions tied to future annual meetings.

Director Badreddin Edris received a grant of restricted stock units and stock options as part of annual compensation.

Director Christopher Nathan Martin was granted 16,377 stock options in Edgewise Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Jonathan C. Fox was granted 16,377 stock options in Edgewise Therapeutics, Inc. as part of a standard equity compensation arrangement.

Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics, Inc., reported transactions involving the sale of common stock.

Jonathan C. Fox, a Director at Edgewise Therapeutics, Inc., reported the acquisition of 339 shares of common stock on April 1, 2026, as part of a quarterly retainer award.

Chief Medical Officer Joanne M. Donovan exercised options and sold 28,662 shares of Edgewise Therapeutics common stock.

Edgewise Therapeutics' Chief Medical Officer, Joanne M. Donovan, sold 21,338 shares of common stock on March 31, 2026, following an option exercise, as part of a pre-arranged 10b5-1 trading plan.

Edgewise Therapeutics CMO Joanne M. Donovan sold 16,358 shares of common stock for approximately $30.98 per share under a pre-arranged 10b5-1 plan.

Edgewise Therapeutics Director Badreddin Edris exercised stock options and subsequently sold 115,471 shares of common stock for an average price of $29.44 per share.

Edgewise Therapeutics Director Jonathan C Fox was granted 473 shares of common stock as a quarterly retainer award.

Edgewise Therapeutics director Christopher Nathan Martin was granted 45,150 stock options with an exercise price of $22.34, vesting monthly over three years.

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, exercised stock options and subsequently sold 100,000 shares of common stock.

Edgewise Therapeutics Director Jonathan C Fox purchased 10,700 shares of common stock for approximately $199,493.

Edgewise Therapeutics CFO Michael Nofi received 43,750 Restricted Stock Units and 262,500 stock options, aligning his long-term interests with the company's performance.

Edgewise Therapeutics, Inc. Director Jonathan C. Fox was granted 728 shares of common stock as a quarterly retainer award.

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, exercised stock options and subsequently sold 100,000 shares of common stock for approximately $1.46 million.

Edgewise Therapeutics, Inc. disclosed new equity grants to its Chief Development Officer, Robert Blaustein, including restricted stock units and stock options.

Edgewise Therapeutics' General Counsel, John R. Moore, filed a Form 4 detailing future RSU vesting, a tax-related stock sale, and new equity grants effective August 12, 2025.